$6.820
+0.436 (+6.40%)收盤時
RNAC 資訊
RNAC 事件
Cartesian Therapeutics Announces Positive Retreatment Data for Descartes-08
Cartesian Therapeutics announced additional positive retreatment data of its lead investigational asset, Descartes-08, in patients with generalized myasthenia gravis, being presented during the Myasthenia Gravis Foundation of America, MGFA, Scientific Session of the 2026 American Association of Neuromuscular and Electrodiagnostic Medicine, AANEM, Annual Meeting being held in Orlando, Florida. 12-Month Retreatment Results: Patients retreated at a median of 16.6 months following completion of initial treatment course experienced greater improvement in MG symptoms compared to initial course of treatment; mean decrease in MG-ADL scores were sustained through 12 months following retreatment. Consistent safety data observed to date supports potential retreatment of Descartes-08 following recurrence of MG symptoms, as clinical benefit was observed with no new safety concerns.
Selecta Biosciences Inc Trading Halted
Selecta Biosciences Inc trading halted, volatility trading pause
Cartesian Therapeutics Secures $150M Financing from K2 HealthVentures
Cartesian Therapeutics announced that it has entered into an agreement with K2 HealthVentures, an alternative investment firm that provides flexible, long-term financing solutions in life sciences, to provide a credit facility of up to $150M including an initial $50M tranche. The proceeds from the initial tranche under the credit facility are expected to allow the Company to accelerate the ongoing investment in the commercial launch preparation activities for Descartes-08 in myasthenia gravis and myositis and to extend cash runway into 2028. The Company also announced progress across its pipeline, including updated timelines for all ongoing trials of Descartes-08, an autologous anti-B cell maturation antigen mRNA chimeric antigen receptor T-cell therapy.
Cartesian Reports FY25 Revenue of $2.797M, Exceeding Expectations
Reports FY25 revenue $2.797M, consensus $1.97M. "Building on a productive year, we look forward to a potentially transformative 2026 as we advance Descartes-08 across several autoimmune indications," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. "Our top priority remains delivering on our Phase 3 AURORA trial in myasthenia gravis, for which we are on track to enroll approximately 100 patients. This trial represents a crucial opportunity to demonstrate the potential of Descartes-08 to improve patient outcomes and redefine the standard-of-care for MG. Descartes-08's ease of use, including, flexible, convenient outpatient administration with no preconditioning chemotherapy, combined with deep and durable responses observed through 12 months following a single course of treatment, and a favorable safety profile, underscore our belief that Descartes-08 holds significant promise to deliver meaningful benefit to patients."
Cartesian Therapeutics Grants 12,050 Stock Options to New Employees
Cartesian Therapeutics announced the granting of inducement awards to two new employees. On February 2, 2026, the Company issued to these employees options to purchase an aggregate of 12,050 shares of the Company's common stock with an exercise price of $6.79, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on February 2, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on February 2, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.
相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。